From Blame to Data: How Medication Error Reporting Systems Drive Patient Safety

A single medication error can have devastating consequences for patients, pharmacists, and institutions. Globally, medication-related errors are responsible for approximately 5% to 41% of all hospital admissions and 22% of readmissions.¹ The annual costs associated with medication errors globally are approximately $42 billion.²

Error reporting and analysis can only decrease error rates if health care shifts its culture from one of punitive blame to one that treats errors as systemic data points for identification and correction. This requires a robust, nonpunitive reporting system coupled with systematic analysis to prevent future harm.

Architecture of Pharmacy Reporting Systems

Pharmacy error reporting systems are standardized processes by which health care professionals can identify, track, and analyze medication errors and near misses to prevent future patient harm. These typically operate across 3 distinct tiers.

The facility-level tier involves internal reporting systems. Local, software-based tracking systems used by pharmacies allow employees to record mistakes and near misses. This standardized reporting across a health care organization enables internal tracking, trend analysis, and comparative analysis. This type of reporting system is an integral tool to identify system-based vulnerabilities.³

At the national level, external voluntary programs are databases that collect data on prescription errors, near misses, and product hazards in a nonpunitive manner. Most can even accept anonymous submissions. Unlike mandatory internal programs, external voluntary programs focus entirely on systemic analysis, public health alerts, and national safety trends.⁴

Depending on the nature of the error, pharmacists can report on several primary national platforms. The Institute for Safe Medication Practices (ISMP) runs the ISMP National Medication Errors Reporting Program. This platform collects data to evaluate root causes and high-alert medications and publishes nationwide safety alerts.⁴ The FDA hosts MedWatch, a program optimized for product use errors, therapeutic failures, lookalike/sound-alike issues, and adverse drug reactions.⁵ And patient safety organizations allow facilities and practitioners to assemble error data safely, without the fear of exposing themselves to legal liability.⁶

Finally, at the state and federal levels, there are legally mandated systems operated by state and federal government agencies. The core objectives of these programs prioritize public safety, provider accountability, and regulatory oversight. Key characteristics include a primary focus on serious harm, root cause analysis, and public dissemination.

Several regulatory agencies are involved at the state and federal levels. State boards of pharmacy and medicine retain the legal authority to impose sanctions, such as administrative fees, restrictions on practice, or revocation of professional licenses, if deemed appropriate.⁷ State departments of health carry out on-site audits and reviews and manage hospital-wide mandatory adverse event reporting systems. In the United States, licensing boards must report adverse practitioner actions and medical malpractice payouts to the National Practitioner Data Bank.⁷

The Ongoing Regulatory Debate: Mandatory vs Voluntary

Voluntary reporting is considered more advantageous for long-term patient safety because its blame-free nature encourages honest, comprehensive information sharing that is invaluable for quality improvement. Mandatory reporting, however, remains essential because it provides accountability and guarantees that failures are not hidden from the public. The Table provides key features of mandatory vs voluntary error reporting systems.

Methodologies for Analyzing Medication Errors

Medication error analysis takes data from mandatory and voluntary reporting systems and transforms it into actionable system improvements by using structured, evidence-based techniques to move away from blame and toward fixing flawed processes.⁸

Root cause analysis (RCA) is a structured method used after specific medication errors to identify underlying system vulnerabilities that may have led to the error. A multidisciplinary team reviews the events, which are typically serious errors, and identifies contributing factors. The objective is to provide actionable, systemic changes to prevent recurrence.⁹

Failure mode and effects analysis (FMEA) is a prospective, proactive process used to evaluate systems, predict where they may fail, assess the potential impact of those failures, and build defenses in the workflow to avoid them. The analysis team breaks down each individual step in the process and calculates a Risk Priority Number (RPN) based on 3 factors: severity, probability of occurrence, and probability of detection. Processes containing a high RPN can then be targeted for improvement.¹⁰

Human factors engineering (HFE) evaluates interactions among humans, the tools they use, and their work environment to analyze errors. This includes user interfaces, cognitive workloads, and physical workspaces. The goal is to implement physical or structural changes that render a specific error impossible or very difficult to repeat.¹¹

Finally, unlike RCA, FMEA, and HFE, aggregate data analysis and trend tracking analyze massive amounts of data over time. Aggregate analysis reveals where systemic vulnerabilities lie across entire institutions or health care networks. This helps organizations detect subtle, repeating failures that may be missed during individual reviews. The goal of tracking aggregate data is to move from a reactive model to one that is predictive and proactive.¹²

Conclusion

Medication error reporting and analysis are integral components in transforming inevitable human error into safer clinical environments. True progress in reducing medication errors requires moving beyond a blame culture toward one of open information sharing without fear of reprisal.

Reporting systems are only as powerful as the analysis and systemic changes they promote. When health care organizations treat medication error data as an opportunity to improve, they can engineer safer clinical environments. Pharmacists must view every error not as a personal failure, but as a critical opportunity to protect the next patient.

About the Author

Kathleen Kenny, PharmD, RPh, earned her doctoral degree from the University of Colorado Anschutz. She has more than 30 years of experience as a community pharmacist and works as a clinical medical writer based in Albuquerque, New Mexico.

REFERENCES

1. Tariq RA, Vashisht R, Sinha A, Scherbak Y. Medication dispensing errors and prevention. In: StatPearls. StatPearls Publishing; 2026-.

2. Medication without harm. World Health Organization. Accessed July 8, 2026. https://www.who.int/initiatives/medication-without-harm

3. Aseeri M, Banasser G, Baduhduh O, Baksh S, Ghalibi N. Evaluation of medication error incident reports at a tertiary care hospital. Pharmacy (Basel). 2020;8(2):69. doi:10.3390/pharmacy8020069

4. Nosek RA, McMeekin J, Rake GW. Standardizing medication error event reporting in the US Department of Defense. In: Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in Patient Safety: From Research to Implementation, Volume 4: Programs, Tools, and Products. Agency for Healthcare Research and Quality (US); 2005.

5. Reporting serious problems to FDA. FDA. Updated September 26, 2025. Accessed July 8, 2026. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda

6. Jones KJ, Cochran GL, Xu L, et al. The association between pharmacist support and voluntary reporting of medication errors: an analysis of MEDMARX data. In: Henriksen K, Battles JB, Keyes MA, Grady ML, eds. Advances in Patient Safety: New Directions and Alternative Approaches, Volume 1: Assessment. Agency for Healthcare Research and Quality; 2008.

7. Adams AJ, Adams J. Does increased state pharmacy regulatory burden lead to better public safety outcomes? Innov Pharm. 2021;12(1):10.24926/iip.v12i1.3598. doi:10.24926/iip.v12i1.3598

8. Rashdan D, Farha RA, Yasin H, Hadi MA. Human factors frameworks in analysis of contributory factors to medication error: a systematic review. Res Social Adm Pharm. 2025;21(9):629-652. doi:10.1016/j.sapharm.2025.04.005

9. Graber ML, Castro GM, Danforth M, et al. Root cause analysis of cases involving diagnosis. Diagnosis (Berl). 2024;11(4):353-368. doi:10.1515/dx-2024-0102

10. Buja A, De Luca G, Ottolitri K, et al. Using failure mode, effect and criticality analysis to improve safety in the cancer treatment prescription and administration process. J Pharm Policy Pract. 2023;16(1):9. doi:10.1186/s40545-023-00512-9

11. Scanlon MC, Karsh BT. Value of human factors to medication and patient safety in the intensive care unit. Crit Care Med. 2010;38(suppl 6):S90-S96. doi:10.1097/CCM.0b013e3181dd8de2

12. Silva SSM, Wabe N, Raban MZ, et al. Characteristics and risk factors of medication incidents across stages of medication management in residential aged care: a longitudinal cohort study of 5700 reported incidents. Drug Saf. 2026;49(2):195-206. doi:10.1007/s40264-025-01602-0